Latest Safety News

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Veris Ltd reports a solid 9% revenue increase in H1 FY26, driven by a strategic pivot to higher-value digital and spatial advisory services, with underlying profits up 69%.

icetana Limited reports a strong first half of 2026 with recurring revenue up 43%, driven by key partnerships and expanded market reach across APAC and the Middle East.

GreenHy2 Limited narrowed its net loss by 16% in FY2025, driven by government grants and initial sales of its new sodium-ion batteries. Strategic partnerships and product diversification position the company for growth in renewable energy storage.

Atlas Pearls reports a challenging first half of FY26 with a 27% drop in revenue and a net loss of $5.2 million, driven by weaker market demand and a shift towards lower-grade pearl sales.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Cryosite Limited reported a robust half-year with revenue up 25% and net profit rising 36%, driven by strong demand in temperature-controlled logistics and a strategic warehouse acquisition that doubles its storage capacity.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

AVADA Group Limited reported an 11% revenue increase to $101.5 million in H1 FY26, driven by strong growth in Queensland and New South Wales and early gains from its business transformation. Despite a statutory loss, adjusted EBITDA improved, setting the stage for a stronger second half.

Zimplats Holdings Limited reported a remarkable half-year performance with revenue up 83% and profit before tax surging over 2,100%, driven by higher metal prices and operational gains. Capital projects and sustainability efforts remain on track amid a challenging Zimbabwean environment.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Saferoads Holdings Limited has reported a return to profitability with a $504k half-year net profit, driven by strong product sales following the sale of its Road Safety Rentals business. The company also announced a fully franked interim dividend of 0.5 cents per share.